Crossmark

Enhanced potency of immune checkpoint inhibitors against poorly immunological solid tumors by immune stimulatory oncolytic adenoviruses-mediated remodeling of the tumor microenvironment

Crossref DOI link: https://doi.org/10.1186/s10020-025-01223-4

Published Online: 2025-05-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ahn, Hyo Min

Jung, Bo-Kyeong

Hong, JinWoo

Hong, Dayoung

Yoon, A-Rum

Yun, Chae-Ok
Funding

Funding for this research was provided by:

KOREA-ISRAEL Industrial R&D Foundation (1415183804)

National Research Foundation of Korea (2015R1A2A1A13027811)
License Information

Text and Data Mining valid from 2025-05-07

Version of Record valid from 2025-05-07
More Information

Article History

Received: 2 December 2024

Accepted: 22 April 2025

First Online: 7 May 2025

Declarations

:

: All animal experiments were approved by the Hanyang University Institutional Animal Care and Use Committee (IACUC) under approval number 2021-0193 A.

: Not applicable.

: Hyo Min Ahn, Bo-Kyeong Jung, and JinWoo Hong are employees of GeneMedicine Co., Ltd. Chae-Ok Yun is the founder and CEO of GeneMedicine Co., Ltd.

Document is current

Any future updates will be listed below